Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex

Abstract

Lipid lowering therapies are crucial to reduce cardiovascular risk, yet outcomes data in women are limited. Further, women are less likely to have hypercholesterolemia diagnosed or treated and more likely to report statin intolerance.1 CLEAR (Cholesterol Lowering via Bempedoic Acid [ECT1002], an ACL-Inhibiting Regimen) Outcomes showed patients with, or at high risk for, cardiovascular disease who are unable or unwilling to take guideline-recommended doses of statins had a significantly lower risk of major adverse cardiovascular events (MACE) with bempedoic acid, an ATP citrate lyase inhibitor, than with placebo.2 CLEAR Outcomes is notable for having 48% (n=6740) female subjects—the highest percentage enrollment of females among contemporary lipid-lowering outcomes trials—affording the opportunity to assess whether improvements in cardiovascular risk seen with bempedoic acid varied by sex.